Europe — EMA
Ocrevus (Ocrelizumab)
GNH USA supplies Ocrevus (Ocrelizumab), a monoclonal antibody for relapsing and primary progressive multiple sclerosis. Request a quote for global supply.
Request sourcing
What is Ocrelizumab?
Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a sterile solution for intravenous infusion use. It is indicated for the treatment of multiple sclerosis in adults, including both relapsing forms and primary progressive disease. GNH USA supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.
What is Ocrelizumab used for?
Ocrevus is indicated for multiple sclerosis, a chronic autoimmune disorder of the central nervous system.
Relapsing forms of multiple sclerosis (RMS): reduces relapse frequency and slows disability progression. Primary progressive multiple sclerosis (PPMS): delays worsening of disability. Active disease activity (MRI lesions): decreases the number of new or enlarging lesions on magnetic resonance imaging.
What are the side effects of Ocrelizumab?
Common Side Effects: - Infusion‑related reactions (fever, chills, flushing) - Upper respiratory tract infection - Headache - Mild rash or pruritus - Nausea - Fatigue
Serious or Rare Side Effects: - Opportunistic infections, including herpesvirus reactivation - Malignancies (e.g., breast cancer, melanoma) - Progressive multifocal leukoencephalopathy (PML) - Hepatitis B reactivation - Severe infusion reactions or anaphylaxis - Autoimmune hepatitis
What precautions apply to Ocrelizumab?
Before initiating therapy, healthcare professionals should consider several safety measures. - Screen for active infections: assess patient history and perform relevant tests. - Vaccination status: administer required vaccines prior to the first infusion. - Monitor liver enzymes: obtain baseline values and repeat periodically. - Test for hepatitis B: screen and manage any positive results before treatment. - Avoid live vaccines during therapy: they may cause severe infection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Ocrelizumab interact with?
Ocrevus may interact with other agents that affect immune function.
Major Interactions (Avoid): - Live vaccines: risk of severe infection. - Concomitant immunosuppressants: heightened infection risk. - Antiviral prophylaxis for hepatitis B reactivation: required if patient is HBV‑positive.
Moderate Interactions (Monitor Closely): - Non‑live vaccines: possible reduced efficacy. - Cytotoxic chemotherapy: monitor blood counts closely. - Other monoclonal antibodies: increased overall immunosuppression.
